Bernadette M. Connaughton's most recent trade in Editas Medicine Inc was a trade of 37,500 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 6, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2025 | 37,500 | 37,500 | - | - | Stock Option (right to buy) | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 5,750 | 5,750 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 May 2025 | 4,165 | 50,952 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2024 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 8,804 | 8,804 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Apr 2024 | 6,501 | 46,787 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Syneos Health Inc - Ordina... | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 4,863 | 14,778 (0%) | 0% | 0 | Class A Common Stock | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 11,371 | 11,371 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2023 | 8,065 | 40,286 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 16 Nov 2022 | 5,998 | 32,221 (0%) | 0% | 0 | Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2022 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Syneos Health Inc - Ordina... | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 2,839 | 9,915 (0%) | 0% | 0 | Class A Common Stock | |
| Editas Medicine Inc | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2021 | 24,732 | 24,732 | - | - | Stock Option (right to buy) | |
| Syneos Health Inc - Ordina... | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 2,364 | 7,076 (0%) | 0% | 0 | Class A Common Stock | |
| Halozyme Therapeutics Inc. | Bernadette M. Connaughton | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 May 2021 | 5,230 | 32,013 | - | 0 | Restricted Stock Units |